^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FPI-2265

    i
    Other names: FPI-2265, Ac225-PSMA I&T, 225Actinium-PSMA-I&T, FPI2265, FPI 2265
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    Alpha radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    AlphaBreak: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2/3, N=60, Recruiting, Fusion Pharmaceuticals Inc.
    New P2/3 trial • Metastases
    |
    FPI-2265
    10ms
    Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (clinicaltrials.gov)
    P2, N=115, Recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    FPI-2265
    over1year
    Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). (clinicaltrials.gov)
    P2, N=100, Recruiting, Excel Diagnostics and Nuclear Oncology Center | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date
    |
    MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    FPI-2265